首页 | 本学科首页   官方微博 | 高级检索  
     


CONTROL OF ANGIOGENESIS BY INHIBITOR OF PHOSPHOLIPASE A2
Authors:Soria Jeannette  Soria Claudine  Yedgar Saul
Affiliation:Beijing Chaoyang Hospital, Capital University of Medical Sciences, Beijing 100020;Hotel Dieu, Paris 75181, France;Laboratoire Difema, Faculte de Medecine et de Phamacie, Rouen 76000, France;Hadassah Hospital, Jerusalem 45120, Israel
Abstract:Objective To investigate the potential effects of angiogenic process by secretory phospholipase A2(sPLA2) inhibitor-HyPE (linking N-derivatized phosphatidyl-ethanolamine to hyaluronic acid) on human bone marrow endothelial cell line (HBME-1). Methods In order to examine the suppressing effects of HyPE on HBME-1 proliferation, migration, and capillary-like tube formation, HBME-1 were activated by angiogenic factor, specifically by basic fibroblast growth factor (b-FGF), vascular endothelial growth factor (VEGF), and oncostatin M (OSM) (at a final concentration of 25, 20, and 2.5 ng/mL, respectively), then HBME-1 proliferation, migration, and tube formation were studied in the absence or presence of HyPE. HBME-1 tube formation was specially analyzed in fibrin gel. Results HyPE effectively inhibited HBME-1 proliferation and migration as a dose-dependent manner,whatever HBME-1 were grown in the control culture medium or stimulated with b-FGF, VEGF, or OSM.In fibrin, the formations of HBME-1 derived tube-like structures were enhanced by all angiogenic factors,but these were strongly suppressed by HyPE. Conclusions The results support the involvement of sPLA2 in angiogenesis. It is proposed that sPLA2inhibitor introduces a novel approach in the control of cancer development.
Keywords:angiogenesis  phospholipase A2 inhibitor  endothelial cell line  PHOSPHOLIPASE  INHIBITOR  ANGIOGENESIS  novel approach  cancer  development  support  involvement  angiogenesis  derived  structures  factors  control  culture medium  Results  manner  fibrin  presence  final  concentration
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号